Early Stage Clinical Development
Since 2002, the Agilent team has been manufacturing and delivering oligo APIs for clinical trials from our cGMP facility in Boulder, Colorado, USA. Manufacturing capabilities include 11 independent suites that create four separate synthesis/purification trains and large scale lyophilization units.
Our 77,000-square-foot facility is equipped to provide you with material throughout your development program. Small to intermediate-scale quantities are produced for toxicology and early clinical development with appropriately scaled synthesis and purification equipment.
Our 77,000-square-foot facility is equipped to provide you with material throughout your development program. Small to intermediate-scale quantities are produced for toxicology and early clinical development with appropriately scaled synthesis and purification equipment.